Crossref
Low dose anti-thymocyte globulin versus basiliximab as induction in standard risk kidney transplant patients: 5-year follow-up
Korean Journal of Transplantation · 2020
DOI: 10.4285/atw2020.op-1026 ↗At a glance
Journal article in Korean Journal of Transplantation, 2020. Written by Candy Cahilog and 4 co-authors.
Abstract (original language)
Není k dispozici žádný abstrakt.
Cite
APA
Cahilog, C., Danguilan, R., David, P. M., Arakama, M., & Pamugas, G. E. (2020). Low dose anti-thymocyte globulin versus basiliximab as induction in standard risk kidney transplant patients: 5-year follow-up. Korean Journal of Transplantation. https://doi.org/10.4285/atw2020.op-1026
Vancouver
Cahilog C, Danguilan R, David PM, Arakama M, Pamugas GE. Low dose anti-thymocyte globulin versus basiliximab as induction in standard risk kidney transplant patients: 5-year follow-up. Korean Journal of Transplantation. 2020. doi:10.4285/atw2020.op-1026
BibTeX
@article{Cahilog2020,
author = {Cahilog, Candy and Danguilan, Romina and David, Paolo Miguel and Arakama, Mel-Hatra and Pamugas, Glenda Eleanor},
title = {Low dose anti-thymocyte globulin versus basiliximab as induction in standard risk kidney transplant patients: 5-year follow-up},
journal = {Korean Journal of Transplantation},
year = {2020},
doi = {10.4285/atw2020.op-1026}
}
EUVIMED